Geoffrey Dusheiko

30.3k total citations · 12 hit papers
285 papers, 18.6k citations indexed

About

Geoffrey Dusheiko is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Geoffrey Dusheiko has authored 285 papers receiving a total of 18.6k indexed citations (citations by other indexed papers that have themselves been cited), including 250 papers in Hepatology, 232 papers in Epidemiology and 27 papers in Infectious Diseases. Recurrent topics in Geoffrey Dusheiko's work include Hepatitis C virus research (235 papers), Hepatitis B Virus Studies (191 papers) and Liver Disease Diagnosis and Treatment (149 papers). Geoffrey Dusheiko is often cited by papers focused on Hepatitis C virus research (235 papers), Hepatitis B Virus Studies (191 papers) and Liver Disease Diagnosis and Treatment (149 papers). Geoffrey Dusheiko collaborates with scholars based in United Kingdom, United States and France. Geoffrey Dusheiko's co-authors include Rachel Westbrook, Jean–Michel Pawlotsky, David J. Brown, Heiner Wedemeyer, Alessio Aghemo, Massimo Puoti, Francesco Negro, Marina Berenguer, Olav Dalgård and Paul Klenerman and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Geoffrey Dusheiko

277 papers receiving 18.0k citations

Hit Papers

EASL Recommendations on T... 1994 2026 2004 2015 2018 2009 2020 2014 2000 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EASL Recommendations on Treatment of Hepatitis C 2018
    2018 1.5k citations Geoffrey Dusheiko et al. Journal of Hepatology profile →
  2. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
    2009 771 citations Geoffrey Dusheiko, Leif Bengtsson et al. profile →
  3. EASL recommendations on treatment of hepatitis C: Final update of the series☆
    2020 707 citations Geoffrey Dusheiko et al. Journal of Hepatology profile →
  4. Natural history of hepatitis C
    2014 683 citations Geoffrey Dusheiko et al. Journal of Hepatology profile →
  5. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
    2000 682 citations Mitchell L. Shiffman, Geoffrey Dusheiko et al. profile →
  6. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
    2014 592 citations Geoffrey Dusheiko, Robert Flisiak et al. profile →
  7. Hepatitis B virus infection
    2018 572 citations Geoffrey Dusheiko et al. profile →
  8. Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and disease
    1994 488 citations Geoffrey Dusheiko et al. Hepatology profile →
  9. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
    2020 341 citations Geoffrey Dusheiko et al. profile →
  10. Hepatitis C
    2015 323 citations Daniel P. Webster, Paul Klenerman et al. The Lancet profile →
  11. Hepatitis C
    2019 279 citations Geoffrey Dusheiko et al. The Lancet profile →
  12. New Approaches to Chronic Hepatitis B
    2023 97 citations Geoffrey Dusheiko, Kosh Agarwal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Geoffrey Dusheiko United Kingdom 60 15.1k 14.6k 2.4k 1.6k 1.1k 285 18.6k
Stuart C. Gordon United States 59 18.4k 1.2× 16.6k 1.1× 2.6k 1.1× 971 0.6× 1.1k 1.0× 359 21.8k
Ira M. Jacobson United States 64 17.0k 1.1× 15.7k 1.1× 3.0k 1.2× 939 0.6× 1.0k 0.9× 338 19.9k
A. Albertí Italy 62 12.5k 0.8× 12.7k 0.9× 1.1k 0.5× 1.0k 0.7× 880 0.8× 400 15.7k
Janice K. Albrecht United States 48 23.6k 1.6× 21.7k 1.5× 2.9k 1.2× 946 0.6× 1.2k 1.0× 117 26.0k
Stanislas Pol France 71 15.1k 1.0× 14.2k 1.0× 3.1k 1.3× 1.1k 0.7× 925 0.8× 484 18.9k
Nezam H. Afdhal United States 76 13.2k 0.9× 13.2k 0.9× 1.4k 0.6× 1.1k 0.7× 2.2k 2.0× 343 19.6k
Jean–Michel Pawlotsky France 82 19.7k 1.3× 17.6k 1.2× 3.5k 1.4× 1.5k 0.9× 2.4k 2.2× 467 24.6k
Jordan J. Feld Canada 61 10.5k 0.7× 10.0k 0.7× 1.7k 0.7× 1.4k 0.9× 1.1k 1.0× 383 13.7k
David L. Thomas United States 72 21.7k 1.4× 21.0k 1.4× 4.2k 1.7× 2.6k 1.6× 1.2k 1.1× 292 27.3k
Marc G. Ghany United States 58 12.0k 0.8× 12.4k 0.8× 1.5k 0.6× 975 0.6× 1.1k 1.0× 188 15.1k

Countries citing papers authored by Geoffrey Dusheiko

Since Specialization
Citations

This map shows the geographic impact of Geoffrey Dusheiko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey Dusheiko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey Dusheiko more than expected).

Fields of papers citing papers by Geoffrey Dusheiko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey Dusheiko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey Dusheiko. The network helps show where Geoffrey Dusheiko may publish in the future.

Co-authorship network of co-authors of Geoffrey Dusheiko

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey Dusheiko. A scholar is included among the top collaborators of Geoffrey Dusheiko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey Dusheiko. Geoffrey Dusheiko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ivancovsky‐Wajcman, Dana, Camila A Picchio, Geoffrey Dusheiko, et al.. (2025). Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology. JHEP Reports. 7(8). 101436–101436.
2.
Giannini, Edoardo G., Nezam H. Afdhal, Samuel H. Sigal, et al.. (2015). Non‐cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. Journal of Gastroenterology and Hepatology. 30(8). 1301–1308. 4 indexed citations
3.
Webster, Daniel P., Paul Klenerman, & Geoffrey Dusheiko. (2015). Hepatitis C. The Lancet. 385(9973). 1124–1135. 323 indexed citations breakdown →
4.
Miller, Michael H., Kosh Agarwal, Ashley Brown, et al.. (2014). Review article: 2014 UK consensus guidelines – hepatitis C management and direct‐acting anti‐viral therapy. Alimentary Pharmacology & Therapeutics. 39(12). 1363–1375. 31 indexed citations
5.
6.
Afdhal, Nezam H., Geoffrey Dusheiko, Edoardo G. Giannini, et al.. (2013). Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology. 146(2). 442–452.e1. 98 indexed citations
7.
Trembling, Paul, Sudeep Tanwar, William Rosenberg, & Geoffrey Dusheiko. (2013). Treatment decisions and contemporary versus pending treatments for hepatitis C. Nature Reviews Gastroenterology & Hepatology. 10(12). 713–728. 17 indexed citations
8.
Afdhal, Nezam H., Geoffrey Dusheiko, Edoardo G. Giannini, et al.. (2011). FINAL RESULTS OF ENABLE 1, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AS AN ADJUNCT FOR ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE ASSOCIATED WITH THROMBOCYTOPENIA. UCL Discovery (University College London). 12 indexed citations
9.
Dusheiko, Geoffrey, Leif Bengtsson, Nathalie Adda, Robert S. Kauffman, & Ira M. Jacobson. (2011). P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study: Abstract P70 Table 1. Gut. 60(Suppl 2). A32.2–A33. 48 indexed citations
10.
Gane, E., E.J. Heathcote, Patrick Marcellin, et al.. (2010). 1006 HBSAG KINETICS OF DECAY AND BASELINE CHARACTERISTICS OF HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B FOLLOWING 3 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT. Journal of Hepatology. 52. S388–S388. 12 indexed citations
11.
Manns, Michael P., Yves Horsmans, Hendrik W. Reesink, et al.. (2008). Safety and Antiviral Activity of Tmc435350 in Treatment-name Genotype 1 Hcv-infected Patients. Hepatology. 48(4). 3 indexed citations
12.
Danta, Mark & Geoffrey Dusheiko. (2008). Acute HCV in HIV-Positive Individuals – A Review. Current Pharmaceutical Design. 14(17). 1690–1697. 26 indexed citations
13.
Danta, Mark, Oliver G. Pybus, Sanjay Bhagani, et al.. (2007). Evidence of international transmission of HCV in pan-European study of HIV-positive men who have sex with men (MSM). Hepatology. 46. 1 indexed citations
14.
Danta, Mark, Oliver G. Pybus, Martin Fisher, et al.. (2005). Evidence for sexual transmission of HCV in recent epidemic in HIV-infected men in Southeast England.. Hepatology. 42. 2 indexed citations
15.
Lauer, Georg M., Eleanor Barnes, Michaela Lucas, et al.. (2004). High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology. 127(3). 924–936. 241 indexed citations
16.
Reignat, Stephanie, Fabio Malacarne, Graham S. Ogg, et al.. (2001). Distinct functional patterns of HBV-specific CD8+cell response in hepatitis B virus infection. Gut. 48. 1 indexed citations
17.
Papatheodoridis, George, et al.. (1998). Predictive factors of histological outcome in posttransplant HCV infection.. UCL Discovery (University College London). 2 indexed citations
18.
Zuckerman, Arie J. & Geoffrey Dusheiko. (1996). Progress towards the comprehensive control of hepatitis B : proceedings of a roundtable meeting held in Windsor, Berkshire, UK, on 25-26 July 1995. 1 indexed citations
19.
Dusheiko, Geoffrey, Ola Weiland, Olle Reichard, et al.. (1994). RESULTS OF A PLACEBO-CONTROLLED STUDY OF RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS-C. UCL Discovery (University College London). 6 indexed citations
20.
Kew, Michael C., Geoffrey Dusheiko, S. Hadziyannis, & A. R. Patterson. (1984). Does delta infection play a part in the pathogenesis of hepatitis B virus related hepatocellular carcinoma?. BMJ. 288(6432). 1727–1727. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stuart C. Gordon Breakdown of academic impact, for papers by Ira M. Jacobson Breakdown of academic impact, for papers by A. Albertí Breakdown of academic impact, for papers by Janice K. Albrecht Breakdown of academic impact, for papers by Stanislas Pol Breakdown of academic impact, for papers by Nezam H. Afdhal Breakdown of academic impact, for papers by Jean–Michel Pawlotsky Breakdown of academic impact, for papers by Jordan J. Feld Breakdown of academic impact, for papers by David L. Thomas Breakdown of academic impact, for papers by Marc G. Ghany
Rankless by CCL
2026